Overexpression of Sphk2 is associated with gefitinib resistance in non-small cell lung cancer

Tumor Biology

Volumn 37, Issue 5, 2016, Pages 6331-6336

  Liu, Wei ^a   Ning, Jinfeng ^a   Li, Chunhong ^a   Hu, Jing ^a   Meng, Qingwei ^a   Lu, Hailing ^a   Cai, Li ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Chemoresistance; EGFR TKI; Gefitinib; Lung cancer; NSCLC; PC 9 GR cells; Proliferation; SphK2

Indexed keywords

GEFITINIB; MESSENGER RNA; SMALL INTERFERING RNA; SPHINGOSINE KINASE 2; PHOSPHOTRANSFERASE; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; SPHINGOSINE KINASE 2, HUMAN;

ANALYTICAL PARAMETERS; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CARCINOGENESIS; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIVITY; CLONOGENESIS; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG CANCER CELL LINE; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TISSUE LEVEL; TUMOR GROWTH; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROTEIN KINASE INHIBITORS; QUINAZOLINES; RNA, SMALL INTERFERING;

EID: 84949509572     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-4480-1     Document Type: Article

References (18)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.
2. Crino L, Weder W, van Meerbeeck J, Felip E, Working Group ESMO. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v103–15.
3. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J Clin Oncol. 2008;26:3552–9.
4. Mok TS et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–57.
5. Brugger W et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol. 2011;29:4113–20.
6. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol. 2008;9:139–50.
7. Shida D, Takabe K, Kapitonov D, Milstien S, Spiegel S. Targeting SphK1 as a new strategy against cancer. Curr Drug Targets. 2008;9:662–73.
8. Oskeritzian CA, Alvarez SE, Hait NC, Price MM, Milstien S, Spiegel S. Distinct roles of sphingosine kinases 1 and 2 in human mast-cell functions. Blood. 2008;111:4193–200.
9. Liu H, Chakravarty D, Maceyka M, Milstien S, Spiegel S. Sphingosine kinases: a novel family of lipid kinases. Prog Nucleic Acid Res Mol Biol. 2002;71:493–511.
10. Kris MG et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290:2149–58.
11. David O, Jett J, LeBeau H, Dy G, Hughes J, Friedman M, et al. Phospho-Akt overexpression in non-small cell lung cancer confers significant stage independent survival disadvantage. Clin Cancer Res. 2004;10:6865–71.
12. Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 2001;61:3986–97.
13. Igarashi N, Okada T, Hayashi S, Fujita T, Jahangeer S, Nakamura S. Sphingosine kinase 2 is a nuclear protein and inhibits DNA synthesis. J Biol Chem. 2003;47:46832–9.
14. Pyne N, Pyne S. Sphingosine 1-phosphate and cancer. Nat Rev Cancer. 2010;10:489–503.
15. Sun DF, Gao ZH, Liu HP, Yuan Y, Qu XJ. Sphingosine-1-phosphate antagonizes the effect of all-trans-retinoic acid (ATRA) in a human colon cancer cell line by modulation of RARb expression. Cancer Lett. 2012;319:182–9.
16. French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL, et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res. 2003;63:5962–9.
17. Miller AV, Alvarez SE, Spiegel S, Lebman DA. Sphingosine kinases and sphingosine-1-phosphate are critical for transforming growth factor beta-induced extracellular signal-regulated kinase 1 and 2 activation and promotion of migration and invasion of esophageal cancer cells. Mol Cell Biol. 2008;28:4142–51.
18. Gao P, Smith CD. Ablation of sphingosine kinase-2 inhibits tumor ell proliferation and migration. Mol Cancer Res. 2011;9:1509–19.